Myeloproliferative Disorder in Noonan Syndrome

@article{Bastida2011MyeloproliferativeDI,
  title={Myeloproliferative Disorder in Noonan Syndrome},
  author={Pilar Bastida and Sixto Garc{\'i}a-Mi{\~n}a{\'u}r and Bego{\~n}a Ezquieta and Jos{\'e} Lu{\'i}s Dapena and Josep S{\'a}nchez de Toledo},
  journal={Journal of Pediatric Hematology/Oncology},
  year={2011},
  volume={33},
  pages={e43–e45}
}
Children with Noonan syndrome (NS) are at increased risk of developing juvenile myelomonocytic leukemia (JMML) or a myeloproliferative disorder associated with NS (MPD/NS) resembling JMML in the first weeks of life; whereas JMML is an aggressive disorder requiring hematopoietic stem cell transplantation, MPD/NS may resolve without treatment and cases with spontaneous remission have also been reported. Two cases of NS with hematologic disorders are described. Diagnosis of the syndrome was… Expand
Functional evaluation of circulating hematopoietic progenitors in Noonan syndrome
TLDR
These tests are a reliable integrative tool that, together with clinical data and other hematological parameters, could help detect NS patients with a high risk for a myeloproliferative evolution. Expand
Diagnosis and treatment of juvenile myelomonocytic leukemia
TLDR
Several clinical trials have been initiated throughout the world to develop suitable pre‐ or post‐allogeneic HSCT treatments and new targeted therapies that are less toxic, to improve patient outcome. Expand
Myelodysplasia and Myeloid Proliferations
TLDR
There are several differences in MDS observed in children and those in adults (discussed later) due to which the classification systems developed for adult MDS are less relevant in children. Expand
Novel approaches to diagnosis and treatment of Juvenile Myelomonocytic Leukemia
TLDR
This review summarizes current approaches to diagnosis and treatment of JMML, highlighting most recent insights into genetic and epigenetic mechanisms underlying the disease, and providing an overview of novel potential therapeutic strategies. Expand
Molecular genetics of MDS/MPN overlap syndromes.
TLDR
This review summarizes the current understanding of the molecular pathogenesis of overlap syndromes and details the impact of somatic mutations in diagnostic, prognostic, and therapeutic decision-making. Expand
Comprehensive Genomic Analysis of Noonan Syndrome and Acute Myeloid Leukemia in Adults: A Review and Future Directions
TLDR
A young adult patient with a novel combined germline PTPN11 and somatic NPM1, IDH1,and BCL6 mutations who presented with fatal AML is described, suggesting an expanded role in aggressive AML. Expand
Severe congenital thrombocytopaenia – first clinical manifestation of Noonan syndrome
TLDR
It is highlighted that severe neonatal thrombocytopaenia is a manifestation that should be considered in the diagnosis and clinical management of Noonan’s syndrome. Expand
Peripheral blood cells from children with RASopathies show enhanced spontaneous colonies growth in vitro and hyperactive RAS signaling
TLDR
These data provide a basis for further investigating of only partially characterized hematological alterations present in children suffering from RASopathies, and may provide new markers for progression toward malignant MPD in these patients. Expand
An International MDS/MPN Working Group’s perspective and recommendations on molecular pathogenesis, diagnosis and clinical characterization of myelodysplastic/myeloproliferative neoplasms
TLDR
This perspective and the recommendations on molecular pathogenesis, diagnosis and clinical characterization for adult onset myelodysplastic/myeloproliferative is the result of a collaborative project endorsed and supported by the MDS Foundation. Expand
Alterations in RAS-MAPK genes in 200 Spanish patients with Noonan and other neuro-cardio-facio-cutaneous syndromes. Genotype and cardiopathy.
TLDR
Molecular characterization of congenital heart diseases now includes the not infrequent dysmorphic Noonan syndrome and a more rigorous clinical diagnosis should be intended as well. Expand
...
1
2
...

References

SHOWING 1-10 OF 26 REFERENCES
Juvenile myelomonocytic leukemia and Noonan syndrome.
TLDR
It is postulate that patients with NS may have an increased incidence of myeloproliferative disorders, which in most cases appears to be benign but may be preleukemic or even lethal. Expand
Respiratory failure, juvenile myelomonocytic leukemia, and neonatal Noonan syndrome.
TLDR
A case of a dysmorphic neonate who presented with bilateral chylous effusions and juvenile myelomonocytic leukemia where NS was confirmed by the presence of PTPN11 mutation is reported. Expand
The mutational spectrum of PTPN11 in juvenile myelomonocytic leukemia and Noonan syndrome/myeloproliferative disease.
TLDR
There is a genotype/phenotype correlation in the spectrum of PTPN11 mutations found in patients with JMML, NS/MPD, and NS, which supports the need to characterize the range of hematologic abnormalities in individuals with NS and to better define the impact of the PTPn11 lesion on the disease course. Expand
Transient abnormal myelopoiesis in Noonan syndrome.
TLDR
An infant affected by Noonan syndrome and presenting with abnormal hemopoiesis is described, and at present, the patient shows a normal hematologic picture. Expand
Recent advances in the pathogenesis and management of juvenile myelomonocytic leukaemia
TLDR
Allogeneic haematopoietic stem cell transplantation is currently the only treatment able to cure JMML, although the high postrelapse rate is of great concern. Expand
Use of human androgen receptor gene analysis to aid the diagnosis of JMML in female noonan syndrome patients
TLDR
The utility of determining the clonal status of the monocyte population by the HUMARA assay in distinguishing JMML and benign myeloproliferation in female NS patients is demonstrated. Expand
Somatic mutations in PTPN11 in juvenile myelomonocytic leukemia, myelodysplastic syndromes and acute myeloid leukemia
We report here that individuals with Noonan syndrome and juvenile myelomonocytic leukemia (JMML) have germline mutations in PTPN11 and that somatic mutations in PTPN11 account for 34% ofExpand
Severe congenital thrombocytopaenia – first clinical manifestation of Noonan syndrome
TLDR
It is highlighted that severe neonatal thrombocytopaenia is a manifestation that should be considered in the diagnosis and clinical management of Noonan’s syndrome. Expand
Juvenile myelomonocytic leukemia and chronic myelomonocytic leukemia
In 1982, chronic myelomonocytic leukemia (CMML) was first classified in the category of myelodysplastic syndromes (MDSs), but it always seemed somewhat out of place compared with the rest of the MDSExpand
Genotypic and phenotypic characterization of Noonan syndrome: New data and review of the literature
TLDR
Findings indicate that individuals with NS with specific mutations in PTPN11 are at risk of developing JMML, and the distribution of these mutations is reported on. Expand
...
1
2
3
...